MAZE

+ Watchlist + Portfolio

Maze Therapeutics, Inc.

Regulated industry Sells to businesses Development stageTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $26.43
52-Week Range: $21.95 – $53.65
Market Cap: $1.46B
P/E (TTM): —
EPS (TTM): -2.48
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 3.22
PEG Ratio: —
Return on Equity: -37.35%
Return on Assets: -21.79%
Gross Margin: 100.00%
Operating Margin: -728.06%
Profit Margin: 0.00%
Current Ratio: 18.31
Debt/Equity: 0.13
Total Debt: $60.42M
Free Cash Flow: $-63.63M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $1.12B

MAZE Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$167.50M	$0.00
Research & Development	$88.19M	$73.94M	$83.50M	$108.45M
Selling, General & Admin	$22.83M	$24.61M	$26.42M	$34.45M
Operating Expenses	$111.03M	$98.55M	$109.91M	$142.90M
Operating Income	-$111.03M	-$98.55M	$57.59M	-$142.90M
EBITDA	-$107.21M	-$94.46M	$60.88M	-$140.50M
Pretax Income	-$114.94M	-$100.42M	$53.40M	-$131.12M
Income Tax	—	$0.00	$1.17M	$0.00
Net Income	-$114.94M	-$100.42M	$52.23M	-$131.12M
Diluted EPS	-3.29	-2.87	0.08	-3.05
Diluted Shares	35.40M	35.40M	43.78M	42.98M

MAZE Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$99.92M	$29.16M	$196.81M	$189.25M
Current Assets	$106.15M	$34.11M	$201.67M	$349.72M
Total Assets	$149.96M	$71.50M	$240.54M	$397.13M
Current Liabilities	$20.78M	$16.32M	$20.67M	$22.56M
Long-Term Debt	—	$20.08M	—	—
Total Debt	$32.05M	$49.62M	$26.63M	$23.31M
Total Liabilities	$432.42M	$445.35M	$551.73M	$42.16M
Retained Earnings	-$295.27M	-$395.69M	-$358.43M	-$489.55M
Shareholders' Equity	-$282.46M	-$373.85M	-$311.18M	$354.97M
Working Capital	$85.37M	$17.79M	$181.00M	$327.16M

MAZE Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$99.20M	-$86.83M	$75.95M	-$111.94M
Capital Expenditure	-$1.97M	-$441.00K	-$1.15M	-$794.00K
Free Cash Flow	-$101.17M	-$87.27M	$74.81M	-$112.73M
Depreciation & Amortisation	$3.82M	$4.09M	$3.30M	$2.40M
Stock-Based Compensation	$6.74M	$8.75M	$9.65M	$16.40M
Investing Cash Flow	-$3.17M	-$441.00K	-$1.15M	-$170.96M
Financing Cash Flow	$1.73M	$16.39M	$92.85M	$275.34M
Net Change in Cash	-$100.64M	-$70.88M	$167.65M	-$7.57M

MAZE Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$20.00M	$0.00
Research & Development	$27.58M	$28.11M	$25.19M	$27.57M	$34.15M	$34.94M
Selling, General & Admin	$7.82M	$8.37M	$7.78M	$10.49M	$12.40M	$13.10M
Operating Expenses	$35.40M	$36.47M	$32.97M	$38.06M	$46.55M	$48.03M
Operating Income	-$35.40M	-$36.47M	-$32.97M	-$38.06M	-$26.55M	-$48.03M
EBITDA	-$32.10M	-$33.03M	-$32.39M	-$37.56M	-$22.90M	-$43.41M
Pretax Income	-$32.79M	-$33.68M	-$30.09M	-$34.57M	-$24.21M	-$44.73M
Income Tax	—	$0.00	$0.00	$0.00	—	—
Net Income	-$32.79M	-$33.68M	-$30.09M	-$34.57M	-$24.21M	-$44.73M
Diluted EPS	-1.15	-0.77	-0.66	-0.65	-0.45	-0.76
Diluted Shares	28.63M	43.80M	45.78M	53.40M	53.90M	59.00M

MAZE Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$294.37M	$264.54M	$316.77M	$189.25M	$198.77M	$202.64M
Receivables	—	—	—	—	$20.00M	—
Current Assets	$299.71M	$271.15M	$391.30M	$349.72M	$379.78M	$420.42M
Total Assets	$332.84M	$303.52M	$422.06M	$397.13M	$419.71M	$531.63M
Current Liabilities	$18.62M	$19.90M	$22.11M	$22.56M	$21.24M	$22.96M
Long-Term Debt	—	—	—	—	$38.83M	$38.96M
Total Debt	$25.82M	$25.01M	$24.18M	$23.31M	$61.22M	$60.42M
Total Liabilities	$40.77M	$41.28M	$42.62M	$42.16M	$78.01M	$78.50M
Retained Earnings	-$391.21M	-$424.89M	-$454.98M	-$489.55M	-$513.75M	-$558.48M
Shareholders' Equity	$292.07M	$262.24M	$379.44M	$354.97M	$341.70M	$453.12M
Working Capital	$281.09M	$251.25M	$369.19M	$327.16M	$358.54M	$397.46M

MAZE Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$29.52M	-$30.05M	-$24.64M	-$27.73M	-$39.11M	-$15.05M
Capital Expenditure	-$299.00K	-$393.00K	-$68.00K	-$34.00K	-$93.00K	-$107.00K
Free Cash Flow	-$29.82M	-$30.45M	-$24.71M	-$27.76M	-$39.21M	-$15.16M
Depreciation & Amortisation	$684.00K	$649.00K	$571.00K	$499.00K	$444.00K	$391.00K
Stock-Based Compensation	$3.23M	$3.24M	$3.86M	$6.07M	$7.11M	$9.19M
Investing Cash Flow	-$299.00K	-$393.00K	-$66.88M	-$103.39M	$6.28M	-$128.51M
Financing Cash Flow	$127.38M	$612.00K	$143.76M	$3.59M	$42.36M	$147.44M
Net Change in Cash	$97.56M	-$29.83M	$52.23M	-$127.53M	$9.52M	$3.88M

Market Snapshot

About

Maze Therapeutics is a genetic medicine biotechnology company developing therapies based on insights from human genetics. The company focuses on common and rare diseases with validated genetic targets.